Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study

被引：1
|
作者：
Parsons, S.
Murawa, P. X.
Koralewski, P.
Kutarska, E.
Kolesnik, O. O.
Stroehlein, M. A.
Lahr, A.
Jaeger, M.
Heiss, M. M.
机构：
[1] City Hosp Nottingham, Nottingham, England
[2] Oddzial Chirurg Onkol, Poznan, Poland
[3] Oddzial Chemioterapii Wojewodzki, Krakow, Poland
[4] Oddzial III Onkol Ginekol, Lublin, Poland
[5] Inst Oncol Acad Med Sci, Kiev, Ukraine
[6] Klinikum Koeln Merheim, Cologne, Germany
[7] Fresenius Biotech GmbH, Munich, Germany
[8] TRION Res GmbH, Martinsried, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3000
引用
收藏
页数：1
相关论文
共 50 条
  • [31] INTRAPERITONEAL THERAPY WITH THE TRIFUNCTIONAL ANTIBODY CATUMAXOMAB IS FEASIBLE AND EFFICACIOUS IN OUTPATIENTS SUFFERING FROM MALIGNANT ASCITES RELATED TO VARIOUS GYNECOLOGIC TUMORS
    Kurbacher, C. M.
    Kurbacher, J. A.
    Herz, S.
    Sperling, S.
    Horn, O.
    Schweitzer, C.
    Nymbach, N.
    Kollberg, G.
    Hildenbrandt, R.
    Bollmann, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1282 - 1282
  • [32] Pooled analysis of two phase III studies provides prognostic indicators for clinical outcome after catumaxomab treatment for malignant ascites
    Bokemeyer, C.
    Heiss, M. M.
    Lordick, F.
    Parsons, S. L.
    Wimberger, P.
    Friccius-Quecke, H.
    ONKOLOGIE, 2013, 36 : 273 - 274
  • [33] Effect of catumaxomab treatment in patients with peritoneal carcinomatosis and malignant ascites due to gastrointestinal cancers on survival.
    Stroehlein, M. A.
    Essing, M. M.
    Hennig, M.
    Seimetz, D.
    Ott, M. G.
    Heiss, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [34] Quality-of-life assessment in patients with malignant ascites: Results of a multicenter phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.
    Gonschior, A.
    Heiss, M. M.
    Moehler, M. H.
    Parsons, S. L.
    Gilet, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] SECOND CYCLE OF CATUMAXOMAB TREATMENT IN PATIENTS WITH MALIGNANT ASCITES: RESULTS FROM THE SECIMAS STUDY
    Oskay-Oezcelik, G.
    Vergote, I. B.
    Santoro, A.
    Marme, F.
    Rosenberg, P.
    Sehouli, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 172 - 173
  • [36] Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites
    Bokemeyer, C.
    Heiss, M.
    Gamperl, H.
    Linke, R.
    Schulze, E.
    Friccius-Quecke, H.
    Lindhofer, H.
    Parsons, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Treatment of malignant ascites with catumaxomab in clinical practice: Results of an observational trial
    Kurbacher, C.
    Sehouli, J.
    Welslau, M.
    von Tempelhoff, G-F
    Kuhfahl, J.
    Marth, C.
    Oettle, H.
    Schmalfeldt, B.
    Schulze, E.
    Kunzmann, V
    ONKOLOGIE, 2013, 36 : 280 - 280
  • [38] Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial
    Zhao, Hui
    Li, Xiaosong
    Chen, Dianjun
    Cai, Jianhua
    Fu, Yan
    Kang, Huanrong
    Gao, Jie
    Gao, Ke
    Du, Nan
    MEDICAL ONCOLOGY, 2015, 32 (02) : 1 - 7
  • [39] Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
    Kou, Furong
    Gong, Jifang
    Li, Yan
    Li, Jian
    Zhang, Xiaotian
    Li, Jie
    Shen, Lin
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (02)
  • [40] Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial
    Hui Zhao
    Xiaosong Li
    Dianjun Chen
    Jianhua Cai
    Yan Fu
    Huanrong Kang
    Jie Gao
    Ke Gao
    Nan Du
    Medical Oncology, 2015, 32
12345